Business Context and Reporting Period
Company: Absci Corp (ABSI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Absci is a clinical-stage biopharmaceutical company utilizing an AI-native "Integrated Drug Creation" platform to design antibody therapeutics. The company focuses on underexplored biological mechanisms with high unmet medical needs. Its lead asset, ABS-201, is an anti-prolactin receptor antibody in Phase 1/2a trials for androgenetic alopecia (AGA) and planned for Phase 2 in endometriosis. The company also maintains a pipeline of partnered programs and preclinical assets.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $2.8 | $4.5 |
| Net Loss | $(115.2) | $(103.1) |
| Operating Loss | $(120.3) | $(108.9) |
| Research & Development Expenses | $81.4 | $63.9 |
| Selling, General & Administrative | $35.1 | $36.2 |
| Cash, Cash Equivalents & Marketable Securities | $144.3 | $112.4 |
| Accumulated Deficit | $(624.8) | $(509.6) |
| Net Cash Used in Operating Activities | $(92.9) | $(72.4) |
Note: The filing does not provide specific gross margin or operating margin percentages due to the pre-revenue nature of the core product pipeline and significant R&D investments.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 38% to $2.8 million, driven by the timing of project-based milestones and a shift in the mix of ongoing partnered programs. In 2025, three partners accounted for 95% of revenue, compared to two partners accounting for 99% in 2024.
- Increased R&D Spend: R&D expenses rose 27% to $81.4 million. This increase was primarily due to $17.3 million in costs for advancing drug creation programs, including $13.1 million in direct external costs for the clinical development of ABS-101 and ABS-201.
- One-Time Gain: The company recognized a $5.1 million gain on the settlement of contingent consideration related to the 2021 Totient, Inc. merger, which partially offset operating expenses.
- Capital Raises: The company raised significant capital in 2025, including a $20.0 million PIPE investment from Advanced Micro Devices (AMD), a $46.7 million public offering in July 2025, and $39.2 million from at-the-market offerings.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management expects to continue incurring significant expenses as it advances internally developed programs through clinical trials and invests in its AI platform. The company believes its current cash position ($144.3 million) is sufficient to fund operations for at least the next 12 months. Strategic focus remains on the HEADLINE Phase 1/2a trial for ABS-201, with interim proof-of-concept data expected in the second half of 2026.
Key Risks and Contingencies
- Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. It will need to raise additional capital to fund operations and development; failure to do so could force a reduction in operations.
- Clinical Uncertainty: Biologic drug development is inherently uncertain. Positive preclinical results do not guarantee clinical success. The company has limited experience conducting large-scale clinical trials.
- Partnership Dependency: Revenue is heavily concentrated among a few partners. Future revenue depends on partners achieving milestones and commercializing products, over which Absci has limited control.
- Regulatory and AI Risks: The company faces evolving regulations regarding AI in drug discovery and potential disruptions to FDA operations due to government funding or staffing issues.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $144.3 million cash balance against the projected burn rate, given the 27% increase in R&D spend.
- ABS-201 Trial Progress: Monitor enrollment and safety data from the HEADLINE Phase 1/2a trial, specifically the transition from Single Ascending Dose (SAD) to Multiple Ascending Dose (MAD) cohorts.
- Revenue Concentration: Assess the risk associated with 95% of revenue coming from just three partners and the lack of recurring milestone/royalty revenue to date.
- AMD Collaboration: Evaluate the strategic impact of the AMD partnership and the $20 million investment on the company's AI computational capabilities.
- ABS-101 Strategy: Confirm the status of the decision to seek a partner for ABS-101 rather than advancing it internally, and any resulting out-licensing agreements.